<b>Background/Objectives</b>: Capivasertib is a selective pan-AKT inhibitor recently approved in combination with fulvestrant for the treatment of hormone receptor-positive (HR+)/HER2- breast cancer with alterations in the PI3K/AKT pathway. This evidence concerns the gene PIK3CA and breast carcinoma.